PNV - Banter and General Comments, page-11106

Moving from Short activity thread:

in reponse to your post Kemery
sorrywhat’s the alternative to “going after global sales” if you were the board?

Continue to raise cash to plough into development?Alls the copycat tech being developed per your comment above points to is thatthis is the future & Polynovo are years (decades even) ahead of others,with the best chance to dominate globally, no?

Aboutyour first point, if I were on the board I would first concentrate on valuablemarkets for BTM (US, Europe) making sure its use is correctly reimbursed by insurance or governmentagencies.

RegardingR&D, you are missing several points:

Integraand Matriderm are not copycat technologies, they existed long before PNV. The factthat Integra, with its US$1.5B revenues, purchased DuraSorb to enter marketssuch as Hernia and Breast sling does not bode well for PNV. Same goes with SuprathelSDRM which is derived from previous development.

The costof R&D:

Itis impossible for all R&D projects to be successful, but you can learn, gatherdata and know how which can be very valuable.

Productsdirectly derived from BTM should not cost much to develop. In fact, for DFU, thecompany told us that one clinical trial (already started) was all we need.

Syntrelis different but since the company already invested in a purpose-built plantand equipment (2020), the heavy lifting should already be done. The question is,why investing in a new plant and specialised equipment if you don’t have a product?The answer is poor execution.

If thecompany does not want to carry the can alone an alliance is always a possibility.
In the past Polynovo partnered for several applications, it completed several co-sponsoredstudies:

TNPwith a US company, which has not been a commercial success, but still allowedPNV to have its first Novosorb human use whilst collecting US$500,000 in cash.

Herniafeasibility study between 2013-2014, which seemed to be destined for acommercial partnership (Annual report 2015, page 6). Unfortunately, the projectwas brought back in house. A company presentation dated September 2015 reveals the name of the US partner Telabio.
Telabio subsequently partnered with Aroa (ARX:ASX) launching Ovitex PP in 2015. ARX generated NZ$40 million (out of 60 mil) in 2023 of sales to Telabio.